Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation.
Standard
Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation. / Kobold, Sebastian; Tams, Sinje; Luetkens, Tim; Cao, Yanran; Sezer, Orhan; Bartels, Britta Marlen; Reinhard, Henrike; Templin, Julia; Bartels, Katrin; Hildebrandt, York; Lajmi, Nesrine; Marx, Andreas; Haag, Friedrich; Bokemeyer, Carsten; Kröger, Nicolaus; Atanackovic, Djordje.
In: Clin Dev Immunol, Vol. 2011, 2011, p. 302145.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation.
AU - Kobold, Sebastian
AU - Tams, Sinje
AU - Luetkens, Tim
AU - Cao, Yanran
AU - Sezer, Orhan
AU - Bartels, Britta Marlen
AU - Reinhard, Henrike
AU - Templin, Julia
AU - Bartels, Katrin
AU - Hildebrandt, York
AU - Lajmi, Nesrine
AU - Marx, Andreas
AU - Haag, Friedrich
AU - Bokemeyer, Carsten
AU - Kröger, Nicolaus
AU - Atanackovic, Djordje
PY - 2011
Y1 - 2011
N2 - The occurrence of SOX2-specific autoantibodies seems to be associated with an improved prognosis in patients with monoclonal gammopathy of undetermined significance (MGUS). However, it is unclear if SOX2-specific antibodies also develop in established multiple myeloma (MM). Screening 1094 peripheral blood (PB) sera from 196 MM patients and 100 PB sera from healthy donors, we detected SOX2-specific autoantibodies in 7.7% and 2.0% of patients and donors, respectively. We identified SOX2(211-230) as an immunodominant antibody-epitope within the full protein sequence. SOX2 antigen was expressed in most healthy tissues and its expression did not correlate with the number of BM-resident plasma cells. Accordingly, anti-SOX2 immunity was not related to SOX2 expression levels or tumor burden in the patients' BM. The only clinical factor predicting the development of anti-SOX2 immunity was application of allogeneic stem cell transplantation (alloSCT). Anti-SOX2 antibodies occurred more frequently in patients who had received alloSCT (n = 74). Moreover, most SOX2-seropositive patients had only developed antibodies after alloSCT. This finding indicates that alloSCT is able to break tolerance towards this commonly expressed antigen. The questions whether SOX2-specific autoantibodies merely represent an epiphenomenon, are related to graft-versus-host effects or participate in the immune control of myeloma needs to be answered in prospective studies.
AB - The occurrence of SOX2-specific autoantibodies seems to be associated with an improved prognosis in patients with monoclonal gammopathy of undetermined significance (MGUS). However, it is unclear if SOX2-specific antibodies also develop in established multiple myeloma (MM). Screening 1094 peripheral blood (PB) sera from 196 MM patients and 100 PB sera from healthy donors, we detected SOX2-specific autoantibodies in 7.7% and 2.0% of patients and donors, respectively. We identified SOX2(211-230) as an immunodominant antibody-epitope within the full protein sequence. SOX2 antigen was expressed in most healthy tissues and its expression did not correlate with the number of BM-resident plasma cells. Accordingly, anti-SOX2 immunity was not related to SOX2 expression levels or tumor burden in the patients' BM. The only clinical factor predicting the development of anti-SOX2 immunity was application of allogeneic stem cell transplantation (alloSCT). Anti-SOX2 antibodies occurred more frequently in patients who had received alloSCT (n = 74). Moreover, most SOX2-seropositive patients had only developed antibodies after alloSCT. This finding indicates that alloSCT is able to break tolerance towards this commonly expressed antigen. The questions whether SOX2-specific autoantibodies merely represent an epiphenomenon, are related to graft-versus-host effects or participate in the immune control of myeloma needs to be answered in prospective studies.
KW - Humans
KW - Prognosis
KW - Cell Line, Tumor
KW - Transplantation, Homologous
KW - Hematopoietic Stem Cell Transplantation
KW - Antibody Specificity/immunology
KW - Autoantibodies/blood/immunology
KW - Epitopes/chemistry/immunology
KW - Immunoglobulin G/blood/immunology
KW - Multiple Myeloma/genetics/immunology/therapy
KW - SOXB1 Transcription Factors/genetics/immunology/metabolism
KW - Humans
KW - Prognosis
KW - Cell Line, Tumor
KW - Transplantation, Homologous
KW - Hematopoietic Stem Cell Transplantation
KW - Antibody Specificity/immunology
KW - Autoantibodies/blood/immunology
KW - Epitopes/chemistry/immunology
KW - Immunoglobulin G/blood/immunology
KW - Multiple Myeloma/genetics/immunology/therapy
KW - SOXB1 Transcription Factors/genetics/immunology/metabolism
U2 - 10.1155/2011/302145
DO - 10.1155/2011/302145
M3 - SCORING: Journal article
VL - 2011
SP - 302145
ER -
